EPIDEMIOLOGY

AND
PREVENTION
OF
VACCINEPREVENTABLE
DISEASES

13TH EDITION

This book was produced by the Communication and Education Branch, National Center for Immunization
and Respiratory Diseases, Centers for Disease Control and Prevention, who is solely responsible for its
content. It was printed and distributed by the Public Health Foundation. For additional copies, contact the
Public Health Foundation at 8772521200 or website http://bookstore.phf.org/.
Slide sets to accompany this book are available on the CDC Vaccines and Immunization website at
http://www.cdc.gov/vaccines/pubs/pinkbook/index.html.
E-mail address for comments, questions or suggestions about the contents of this book: [email protected].

Edited by:
Jennifer Hamborsky, MPH, MCHES
Andrew Kroger, MD, MPH
Charles (Skip) Wolfe

U.S.Department of
Health and Human Services
Centers for Disease
Control and Prevention
April, 2015

On the cover
This illustration depicts the influenza virus.
Graphic created by Dan J. Higgins, Division of Communication Services, CDC

Suggested Citation:
Centers for Disease Control and Prevention.
Epidemiology and Prevention of Vaccine-Preventable Diseases.
Hamborsky J, Kroger A, Wolfe S, eds. 13th ed. Washington D.C.
Public Health Foundation, 2015.

Use of trade names and commercial sources is for identification only and does not imply endorsement by the
Public Health Services or the U.S. Department of Health and Human Services. References to non-CDC sites
on the Internet are provided as a service to readers and do not constitute or imply endorsement of these
organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not
responsible for the content of these sites. URL addresses were current as of the date of publication.

The editors would like to thank Dr. William L. Atkinson, who summarized, standardized and compiled
CDCs vaccine-preventable disease and vaccine teaching materials to create the Pink Book.

He just thought it up and did it. Apocalypse Now

Milestones in the History of Vaccination

400BCE

Hippocrates describes
diphtheria, epidemic jaundice,
and other conditions
ii

1100s

Variolation for smallpox first

reported in China

1721

Variolation introduced
into Great Britain

1796

Edward Jenner inoculates James Phipps with

cowpox, and calls the procedure vaccination
("vacca" is Latin for cow)

Table of Contents
1 Principles of Vaccination
Immunology and Vaccine-Preventable Diseases. . . . . . . . . . . . . . . . 1
Classification of Vaccines. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
Selected References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7

2 General Recommendations on Immunization

Timing and Spacing of Vaccines. . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
Adverse Reactions Following Vaccination . . . . . . . . . . . . . . . . . . . 15
Contraindications and Precautions to Vaccination . . . . . . . . . . . . 17
Invalid Contraindications to Vaccination. . . . . . . . . . . . . . . . . . . . 24
Screening for Contraindications and Precautions to Vaccination. . . 28
Selected References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31

3 Immunization Strategies for Healthcare Practices

and Providers

The Need for Strategies to Increase Immunization Levels. . . . . . . . 33

The AFIX Approach . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
Other Essential Strategies. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39
Selected References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45

4 Vaccine Safety
The Importance of Vaccine Safety Programs. . . . . . . . . . . . . . . . . 47
Sound Immunization Recommendations and Policy . . . . . . . . . . . 49
Assessing and Monitoring Safety of Vaccines. . . . . . . . . . . . . . . . . 50
Vaccine Injury Compensation. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54
The Immunization Providers Role . . . . . . . . . . . . . . . . . . . . . . . . 55
Selected References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60

5 Storage and Handling

Vaccine Storage and Handling . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63
Receiving and Unpacking Vaccine Deliveries . . . . . . . . . . . . . . . . . 66

Vaccine Storage and Temperature Monitoring Equipment. . . . . . . 67

Vaccine and Diluent Placement and Labeling. . . . . . . . . . . . . . . . . 70
Vaccine Storage Troubleshooting. . . . . . . . . . . . . . . . . . . . . . . . . . 71
Vaccine and Diluent Inventory Control . . . . . . . . . . . . . . . . . . . . . 73
Selected References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77

6 Vaccine Administration
Staff Training and Education. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 79
Patient Care Before Administering Vaccine . . . . . . . . . . . . . . . . . . 80
Patient Care During Vaccine Administration. . . . . . . . . . . . . . . . . 83
Infection Control. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 87
Vaccine Preparation. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 88

Milestones in the History of Vaccination

1870

Louis Pasteur creates the

first live attenuated bacterial
vaccine (chicken cholera)

1884-85

Pasteur creates the first

live attenuated viral vaccine for
use in humans

1900

Paul Ehrlich formulates

receptor theory of immunity

1901

First Nobel Prize in Medicine

to von Behring for
diphtheria antitoxin

1909

Theobald Smith discovers a

method for inactivating
diphtheria toxin
iii

Table of Contents
Route and Site. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 91
Nonstandard Administration. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99
Managing Acute Vaccine Reactions. . . . . . . . . . . . . . . . . . . . . . . 100
Documentation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 101
Strategies to Prevent Administration Errors. . . . . . . . . . . . . . . . . 102
Vaccine Adverse Event Reporting System (VAERS). . . . . . . . . . . . 104
Selected References and Resources . . . . . . . . . . . . . . . . . . . . . . . 104

7 Diphtheria

Corynebacterium diphtheriae. . . . . . . . . . . . . . . . . . . . . . . . . . . . 107

Pathogenesis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 107
Clinical Features. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 108
Complications. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 109
Laboratory Diagnosis. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 110
Medical Management . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 110
Epidemiology. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 111
Secular Trends in the United States. . . . . . . . . . . . . . . . . . . . . . . 112
Diphtheria Toxoid . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 113
Vaccination Schedule and Use. . . . . . . . . . . . . . . . . . . . . . . . . . . 114
Contraindications and Precautions to Vaccination . . . . . . . . . . . 115
Adverse Events Following Vaccination. . . . . . . . . . . . . . . . . . . . . 115
Adverse Reactions Following Vaccination . . . . . . . . . . . . . . . . . . 115
Vaccine Storage and Handling. . . . . . . . . . . . . . . . . . . . . . . . . . . 116
Suspect Case Investigation and Control. . . . . . . . . . . . . . . . . . . . 116
Selected References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 117

8 Haemophilus influenzae

Haemophilus influenzae . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 119

Pathogenesis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 120
Clinical Features. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 121
Laboratory Diagnosis. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 121
Medical Management . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 122
Epidemiology. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 123
Secular Trends in the United States. . . . . . . . . . . . . . . . . . . . . . . 123
Haemophilus influenzae type b Vaccines. . . . . . . . . . . . . . . . . . . 125
Vaccination Schedule and Use. . . . . . . . . . . . . . . . . . . . . . . . . . . 126
Monvalent Vaccines. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 128
Combination Vaccines. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 130
Contraindications and Precautions to Vaccination . . . . . . . . . . . 131
Adverse Reactions Following Vaccination . . . . . . . . . . . . . . . . . . 132
Vaccine Storage and Handling. . . . . . . . . . . . . . . . . . . . . . . . . . . 132
Surveillance and Reporting of Hib Disease . . . . . . . . . . . . . . . . . 132
Selected References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 132

Milestones in the History of Vaccination

1919

Calmette and Guerin create

BCG, the first live attenuated
bacterial vaccine for humans
iv

1923

First whole-cell pertussis

vaccine tested
Gaston Ramon develops
diphtheria toxoid

1926

Ramon and Christian Zoeller

develop tetanus toxoid

1931

Goodpasture describes a
technique for viral culture
in hens eggs

1936

Thomas Francis and Thomas

Magill develop the first
inactivated influenza vaccine

Table of Contents
9 Hepatitis A
Hepatitis A Virus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 135
Pathogenesis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 135
Clinical Features. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 136
Complications. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 136
Laboratory Diagnosis. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 136
Medical Management . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 137
Epidemiology. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 137
Secular Trends in the United States. . . . . . . . . . . . . . . . . . . . . . . 139
Case Definition . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 141
Hepatitis A Vaccine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 141
Vaccination Schedule and Use. . . . . . . . . . . . . . . . . . . . . . . . . . . 142
Contraindications and Precautions to Vaccination . . . . . . . . . . . 146
Adverse Reactions Following Vaccination . . . . . . . . . . . . . . . . . . 147
Vaccine Storage and Handling. . . . . . . . . . . . . . . . . . . . . . . . . . . 147
Postexposure Prophylaxis. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 147
Selected References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 147

10 Hepatitis B
Hepatitis B Virus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 149
Clinical Features. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 150
Complications. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 151
Laboratory Diagnosis. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 152
Medical Management . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 154
Epidemiology. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 154
Secular Trends in the United States. . . . . . . . . . . . . . . . . . . . . . . 156
Hepatitis B Prevention Strategies. . . . . . . . . . . . . . . . . . . . . . . . . 157
Hepatitis B Vaccine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 158
Vaccination Schedule and Use. . . . . . . . . . . . . . . . . . . . . . . . . . . 161
Serologic Testing of Vaccine Recipients. . . . . . . . . . . . . . . . . . . . 166
Postexposure Management . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 168
Contraindications and Precautions to Vaccination . . . . . . . . . . . 172
Adverse Events Following Vaccination. . . . . . . . . . . . . . . . . . . . . 172
Adverse Reactions Following Vaccination . . . . . . . . . . . . . . . . . . 172
Vaccine Storage and Handling. . . . . . . . . . . . . . . . . . . . . . . . . . . 173
Selected References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 173

11 Human Papillomavirus
Human Papillomavirus. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 175
Pathogenesis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 175
Clinical Features. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 176
Laboratory Diagnosis. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 176
Medical Management . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 177
Epidemiology. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 177
Disease Burden in the United States . . . . . . . . . . . . . . . . . . . . . . 178
Prevention . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 178

Milestones in the History of Vaccination

1948

John Enders and colleagues

isolate Lansing Type II
poliovirus in human cell line



1954

Enders and Peebles

isolate measles virus
Francis Field Trial of inactivated
polio vaccine

1955

Inactivated polio vaccine

licensed

1961

Human diploid cell line

developed

1963

Measles vaccine licensed

Trivalent oral polio
vaccine licensed
v

Table of Contents
Human Papillomavirus Vaccine. . . . . . . . . . . . . . . . . . . . . . . . . . 179
Vaccination Schedule and Use. . . . . . . . . . . . . . . . . . . . . . . . . . . 181
Contraindications and Precautions to Vaccination . . . . . . . . . . . 183
Adverse Reactions Following Vaccination . . . . . . . . . . . . . . . . . . 184
Vaccine Storage and Handling. . . . . . . . . . . . . . . . . . . . . . . . . . . 184
Selected References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 185

12 Influenza
Influenza Virus. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 187
Pathogenesis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 190
Clinical Features. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 190
Complications. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 190
Impact of Influenza . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 191
Laboratory Diagnosis. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 192
Epidemiology. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 192
Secular Trends in the United States. . . . . . . . . . . . . . . . . . . . . . . 193
Influenza Vaccines . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 193
Vaccination Schedule and Use. . . . . . . . . . . . . . . . . . . . . . . . . . . 196
Contraindications and Precautions to Vaccination . . . . . . . . . . . 199
Adverse Events Following Vaccination. . . . . . . . . . . . . . . . . . . . . 200
Adverse Reactions Following Vaccination . . . . . . . . . . . . . . . . . . 201
Vaccine Storage and Handling. . . . . . . . . . . . . . . . . . . . . . . . . . . 203
Strategies for Improving Influenza Vaccine Coverage. . . . . . . . . . 203
Antiviral Agents for Influenza. . . . . . . . . . . . . . . . . . . . . . . . . . . . 204
Nosocomial Influenza Control. . . . . . . . . . . . . . . . . . . . . . . . . . . 205
Influenza Surveillance. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 206
Selected References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 206

13 Measles
Measles Virus. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 209
Pathogenesis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 209
Clinical Features. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 210
Complications. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 210
Laboratory Diagnosis. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 212
Epidemiology. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 213
Secular Trends in the United States. . . . . . . . . . . . . . . . . . . . . . . 214
Measles Vaccine. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 217
Vaccination Schedule and Use. . . . . . . . . . . . . . . . . . . . . . . . . . . 218
Contraindications and Precautions to Vaccination . . . . . . . . . . . 222
Adverse Events Following Vaccination. . . . . . . . . . . . . . . . . . . . . 225
Adverse Reactions Following Vaccination . . . . . . . . . . . . . . . . . . 226
Vaccine Storage and Handling. . . . . . . . . . . . . . . . . . . . . . . . . . . 227
Selected References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 228

Milestones in the History of Vaccination

1965

Bifurcated needle for

smallpox vaccine licensed

vi

1966

World Health Assembly

calls for global smallpox
eradication

1967

Maurice Hilleman develops

Jeryl Lynn strain of
mumps virus

1969

Stanley Plotkin develops

RA 27/3 strain of rubella
vaccine virus

1971

MMR vaccine licensed

Table of Contents
14 Meningococcal Disease

Neisseria meningitidis. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 231

Pathogenesis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 232
Clinical Features. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 232
Laboratory Diagnosis. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 233
Medical Management . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 234
Epidemiology. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 234
Secular Trends in the United States. . . . . . . . . . . . . . . . . . . . . . . 234
Meningococcal Vaccines . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 236
Vaccination Schedule And Use. . . . . . . . . . . . . . . . . . . . . . . . . . . 239
Contraindications and Precautions to Vaccination . . . . . . . . . . . 241
Adverse Events Following Vaccination. . . . . . . . . . . . . . . . . . . . . 241
Adverse Reactions Following Vaccination . . . . . . . . . . . . . . . . . . 242
Vaccine Storage and Handling. . . . . . . . . . . . . . . . . . . . . . . . . . . 242
Surveillance and Reporting of Meningococcal Disease . . . . . . . . 243
Antimicrobial Chemoprophylaxis. . . . . . . . . . . . . . . . . . . . . . . . . 243
Selected References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 244

15 Mumps
Mumps Virus. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 247
Pathogenesis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 247
Clinical Features. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 247
Complications. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 248
Laboratory Diagnosis. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 249
Epidemiology. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 251
Secular Trends in the United States. . . . . . . . . . . . . . . . . . . . . . . 251
Mumps Vaccine. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 253
Vaccination Schedule and Use. . . . . . . . . . . . . . . . . . . . . . . . . . . 253
Contraindications and Precautions to Vaccination . . . . . . . . . . . 255
Adverse Events Following Vaccination. . . . . . . . . . . . . . . . . . . . . 256
Adverse Reactions Following Vaccination . . . . . . . . . . . . . . . . . . 257
Vaccine Storage and Handling. . . . . . . . . . . . . . . . . . . . . . . . . . . 257
Selected References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 257

16 Pertussis

Bordetella pertussis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 261

Pathogenesis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 261
Clinical Features. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 261
Complications. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 262
Laboratory Diagnosis. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 263
Medical Management . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 265
Epidemiology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 265
Secular Trends in the United States. . . . . . . . . . . . . . . . . . . . . . . 266

Milestones in the History of Vaccination

1977

Last indigenous case

of smallpox
(Somalia)

1979

Last wild poliovirus

transmission in the U.S.

1981

First hepatitis B
vaccine licensed

1983

Smallpox vaccine withdrawn

from civilian market

1986

First recombinant vaccine

licensed (hepatitis B)
National Childhood
Vaccine Injury Act

vii

Table of Contents
Pertussis Vaccines. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 267
Vaccination Schedule and Use. . . . . . . . . . . . . . . . . . . . . . . . . . . 269
Combination Vaccines Containing DTaP. . . . . . . . . . . . . . . . . . . 272
Other DTaP Issues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 273
Contraindications and Precautions to Vaccination . . . . . . . . . . . 274
Adverse Reactions Following Vaccination . . . . . . . . . . . . . . . . . . 275
Vaccine Storage and Handling. . . . . . . . . . . . . . . . . . . . . . . . . . . 276
Selected References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 277

17 Pneumococcal Disease

Streptococcus pneumoniae . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 279

Clinical Features. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 280
Laboratory Diagnosis. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 282
Medical Management . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 283
Epidemiology. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 283
Secular Trends in the United States. . . . . . . . . . . . . . . . . . . . . . . 284
Pneumococcal Vaccines. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 284
Vaccination Schedule and Use. . . . . . . . . . . . . . . . . . . . . . . . . . . 287
Contraindications and Precautions to Vaccination . . . . . . . . . . . 291
Adverse Events Following Vaccination. . . . . . . . . . . . . . . . . . . . . 292
Adverse Reactions Following Vaccination . . . . . . . . . . . . . . . . . . 292
Vaccine Storage and Handling. . . . . . . . . . . . . . . . . . . . . . . . . . . 293
Goals and Coverage Levels. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 293
Selected References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 294

18 Poliomyelitis
Poliovirus. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 297
Pathogenesis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 297
Clinical Features. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 298
Laboratory Testing. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 299
Epidemiology. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 299
Secular Trends in the United States. . . . . . . . . . . . . . . . . . . . . . . 300
Poliovirus Vaccines. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 301
Vaccination Schedule and Use. . . . . . . . . . . . . . . . . . . . . . . . . . . 303
Polio Vaccination of Adults. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 305
Contraindications And Precautions To Vaccination. . . . . . . . . . . 306
Adverse Reactions Following Vaccination . . . . . . . . . . . . . . . . . . 306
Vaccine Storage and Handling. . . . . . . . . . . . . . . . . . . . . . . . . . . 307
Outbreak Investigation and Control . . . . . . . . . . . . . . . . . . . . . . 308
Polio Eradication. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 308
Postpolio Syndrome. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 309
Selected References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 310

Milestones in the History of Vaccination

1989

Two-dose measles vaccine

recommendation

viii

1990

First polysaccharide conjugate

vaccine licensed
(Haemophilus influenzae
type b)

1994

Polio elimination certified

in the Americas
Vaccines for Children
program begins

1995

Varicella vaccine licensed

Hepatitis A vaccine licensed
First harmonized childhood
immunization schedule published

1996

Acellular pertussis vaccine

licensed for infants

Table of Contents
19 Rotavirus
Rotavirus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 311
Pathogenesis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 311
Clinical Features. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 312
Complications. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 312
Laboratory Diagnosis. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 312
Epidemiology. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 313
Rotavirus Disease in the United Staters Pre and Post Vaccine
Introduction. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 314
Rotavirus Vaccines. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 315
Vaccination Schedule and Use. . . . . . . . . . . . . . . . . . . . . . . . . . . 317
Contraindications and Precautions to Vaccination . . . . . . . . . . . 319
Adverse Events Following Vaccination. . . . . . . . . . . . . . . . . . . . . 320
Adverse Reactions Following Vaccination . . . . . . . . . . . . . . . . . . 321
Vaccine Storage and Handling. . . . . . . . . . . . . . . . . . . . . . . . . . . 321
Rotavirus Surveillance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 322
Selected References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 322

20 Rubella
Rubella Virus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 325
Pathogenesis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 325
Clinical Features. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 325
Complications. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 326
Congenital Rubella Syndrome . . . . . . . . . . . . . . . . . . . . . . . . . . . 326
Laboratory Diagnosis. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 327
Epidemiology. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 328
Secular Trends in the United States. . . . . . . . . . . . . . . . . . . . . . . 329
Rubella Vaccine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 330
Vaccination Schedule and Use. . . . . . . . . . . . . . . . . . . . . . . . . . . 331
Rubella Immunity. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 333
Contraindications and Precautions to Vaccination . . . . . . . . . . . 334
Adverse Events Following Vaccination. . . . . . . . . . . . . . . . . . . . . 336
Adverse Reactions Following Vaccination . . . . . . . . . . . . . . . . . . 336
Rubella Vaccination of Women of Childbearing Age. . . . . . . . . . 337
Vaccine Storage and Handling. . . . . . . . . . . . . . . . . . . . . . . . . . . 338
Strategies to Decrease Rubella and CRS . . . . . . . . . . . . . . . . . . . 338
Selected References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 339

21 Tetanus
Clostridium tetani . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 341
Pathogenesis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 342
Clinical Features. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 342
Complications. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 343

Milestones in the History of Vaccination

1997

Sequential polio vaccination

recommended

1998

First rotavirus
vaccine licensed

1999

Exclusive use of inactivated

polio vaccine recommended
Rotavirus vaccine withdrawn

2000

Pneumococcal
conjugate vaccine
licensed for infants

2003

Live attenuated influenza

vaccine licensed

ix

Table of Contents
Laboratory Diagnosis. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 343
Medical Management . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 343
Wound Management. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 344
Epidemiology. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 344
Secular Trends in the United States. . . . . . . . . . . . . . . . . . . . . . . 345
Tetanus Toxoid. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 346
Vaccination Schedule and Use. . . . . . . . . . . . . . . . . . . . . . . . . . . 347
Contraindications and Precautions to Vaccination . . . . . . . . . . . 349
Adverse Events Following Vaccination. . . . . . . . . . . . . . . . . . . . . 349
Adverse Reactions Following Vaccination . . . . . . . . . . . . . . . . . . 349
Vaccine Storage and Handling. . . . . . . . . . . . . . . . . . . . . . . . . . . 350
Selected References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 350

22 Varicella
Varicella Zoster Virus. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 353
Pathogenesis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 353
Clinical Features. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 353
Complications. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 355
Laboratory Diagnosis. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 357
Epidemiology. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 358
Secular Trends in the United States. . . . . . . . . . . . . . . . . . . . . . . 359
Vaccines Containing Varicella Virus. . . . . . . . . . . . . . . . . . . . . . . 360
Vaccination Schedule and Use. . . . . . . . . . . . . . . . . . . . . . . . . . . 363
Varicella Immunity. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 367
Contraindications and Precautions to Vaccination . . . . . . . . . . . 368
Adverse Reactions Following Vaccination . . . . . . . . . . . . . . . . . . 372
Transmission of Varicella Vaccine Virus. . . . . . . . . . . . . . . . . . . . 373
Vaccine Storage and Handling. . . . . . . . . . . . . . . . . . . . . . . . . . . 373
Varicella Zoster Immune Globulin . . . . . . . . . . . . . . . . . . . . . . . . 374
Selected References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 375

APPENDICES
A Schedules and Recommendations
Immunization Schedules on the Web. . . . . . . . . . . . . . . . . . . . . . . A-1
Recommended Immunization Schedules for Persons
Aged 0 Through 18 Years. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A-2
Recommended Adult Immunization Schedule. . . . . . . . . . . . . . . . A-8
Recommended and Minimum Ages and Intervals
Between Doses of Routinely Recommended Vaccines . . . . . . . . A-13
Summary of Recommendations
for Child/Teen Immunization. . . . . . . . . . . . . . . . . . . . . . . . . . . A-15
Summary of Recommendations for Adult Immunization. . . . . . A-20

Milestones in the History of Vaccination



2004

2004

Indigenous transmission of
Inactivated influenza
rubella virus interrupted
vaccine recommended for all
children 623 months of age
x

2005

Acellular pertussis vaccines

licensed for adolescents
and adults

2005

MMR-varicella (MMRV)
licensed

2006

 Second generation rotavirus

vaccine licensed

Table of Contents
Recommended intervals between administration
of immune globulin preparations and measles-or
varicella-containing vaccine. . . . . . . . . . . . . . . . . . . . . . . . . . . . A-24
Healthcare Personnel Vaccination Recommendations. . . . . . . . A-25
Vaccination of Persons with Primary and Secondary Immune
Deficiencies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A-26
Guide to Contraindications and Precautions
to Commonly Used Vaccines. . . . . . . . . . . . . . . . . . . . . . . . . . . A-28
Guide to Contraindications and Precautions
to Commonly Used Vaccines in Adults. . . . . . . . . . . . . . . . . . . . A-30

B Vaccines
U.S Vaccines. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . B-1
Selected Discontinued U.S. Vaccines. . . . . . . . . . . . . . . . . . . . . . . B-5
Vaccine Excipient and Media Summary, by Vaccine. . . . . . . . . . . . B-7
Latex in Vaccine Packaging. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . B-11
Thimerosal Table. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . B-13
Foreign Language Terms. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . B-15

C Vaccine Information Statements

Its Federal Law. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . C-1
Instructions for Use of VISs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . C-3
VIS Questions and Answers. . . . . . . . . . . . . . . . . . . . . . . . . . . . . C-4
CDCs Vaccine Information Statement Webpage. . . . . . . . . . . C-9

D Vaccine Safety
The Vaccine Adverse Event Reporting System (VAERS) . . . . . . . . D-1
The Vaccine Injury Compensation Program (VICP). . . . . . . . . . . D-3
Vaccine Injury Table. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . D-5
Countermeasures Injury Compensation Program (CICP). . . . . . . D-7

E Data and Statistics

Reported Cases and Deaths from Vaccine Preventable Diseases,
United States, 1950-2013 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . E-1
Impact of Vaccines in the 20th and 21st Centuries. . . . . . . . . . . . E-7
Vaccine Coverage Levels, United States, 1962-2012 . . . . . . . . . . . E-8

F Immunization Resources

CDC Contact Information and Resources . . . . . . . . . . . . . . . . . . .

Selected Online Resources. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Contact Information: Selected Vaccine Manufacturers and
Distributors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Immunization Grantees. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

F-1
F-2
F-3
F-4

Milestones in the History of Vaccination

2006

 First human papillomavirus

vaccine licensed

2006

First herpes zoster

vaccined licensed

2009

H1N1 influenza
pandemic declared

2010

Influenza vaccine
recommended for all persons
6 months and older

2013

First quadrivalent influenza

vaccine licensed

xi